\-\ Texto\\:\\ \ \(0\)\
\-\ no\\ endocrine\\,\\ metabolic\\ or\\ toxic\\ abnormalities\\ were\\ identified\\.\ \(0\)\
\-\ there\\ is\\ no\\ treatment\\ for\\ fahr\\ disease\\.\ \(0\)\
\-\ symmetric\\ basal\\ ganglia\\ and\\ dentate\\ nucleus\\ calcifications\\.\ \(0\)\
\-\ fahr\\ disease\ \(0\)\
\-\ \\â\\€\\¢\\ benign\\ basal\\ ganglia\\ calcification\\ associated\\ with\\ aging\ \(0\)\
\-\ \\â\\€\\¢\\ endocrine\\:\\ hyper\\/hypoparathyroidism\\,\\ hypothyroidism\ \(0\)\
\-\ \\â\\€\\¢\\ metabolic\\:\\ \\ mitochondrial\\ disorders\ \(0\)\
\-\ \\â\\€\\¢\\ postinflammatory\\:\\ \\ tuberculosis\\,\\ toxoplasmosis\\,\\ cystercercosis\\,\\ congenital\\ hiv\\,\\ syphilis\ \(0\)\
\-\ \\â\\€\\¢\\ congenital\\:\\ \\ tuberous\\ sclerosis\\,\\ down\\ syndrome\\,\\ neurofibromatosis\ \(0\)\
\-\ \\â\\€\\¢\\ toxic\\:\\ \\ carbon\\ monoxide\\,\\ chemotherapy\\,\\ radiation\\ therapy\\,\\ lead\\ intoxication\ \(0\)\
\-\ 72\\ y\\.o\\.\\ woman\\ with\\ progressive\\ dementia\\.\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ fahr\\:\\ 0\\.1583753958578549\ \(0\)\
\-\ endocrine\\:\\ 0\\.11624522855715026\ \(0\)\
\-\ toxic\\:\\ 0\\.11008474580650943\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.10331962757775084\ \(0\)\
\-\ hyper\\/hypoparathyroidism\\:\\ 0\\.0968738288347967\ \(0\)\
\-\ ganglia\\:\\ 0\\.09610697071376224\ \(0\)\
\-\ metabolic\\:\\ 0\\.09275601261169031\ \(0\)\
\-\ cystercercosis\\:\\ 0\\.08925682685062147\ \(0\)\
\-\ basal\\:\\ 0\\.08561620875029392\ \(0\)\
\-\ postinflammatory\\:\\ 0\\.08480116632196032\ \(0\)\
\-\ dentate\\:\\ 0\\.07718416433778509\ \(0\)\
\-\ mitochondrial\\:\\ 0\\.07549020082319984\ \(0\)\
\-\ aging\\:\\ 0\\.07157069594475222\ \(0\)\
\-\ intoxication\\:\\ 0\\.07052333133151789\ \(0\)\
\-\ congenital\\:\\ 0\\.06868481251961402\ \(0\)\
\-\ monoxide\\:\\ 0\\.06787319883902461\ \(0\)\
\-\ carbon\\:\\ 0\\.06511150182494872\ \(0\)\
\-\ syphilis\\:\\ 0\\.06290632934734267\ \(0\)\
\-\ dementia\\:\\ 0\\.06290632934734267\ \(0\)\
\-\ \\:\\:\\ 0\\.062103011867618955\ \(0\)\
\-\ nucleus\\:\\ 0\\.06025619685484939\ \(0\)\
\-\ toxoplasmosis\\:\\ 0\\.06025619685484939\ \(0\)\
\-\ hypothyroidism\\:\\ 0\\.05504237290325471\ \(0\)\
\-\ 72\\:\\ 0\\.05324424736719096\ \(0\)\
\-\ hiv\\:\\ 0\\.05206572505561296\ \(0\)\
\-\ neurofibromatosis\\:\\ 0\\.05188103144774064\ \(0\)\
\-\ tuberous\\:\\ 0\\.051699390766958106\ \(0\)\
\-\ lead\\:\\ 0\\.04502219288649894\ \(0\)\
\-\ disorders\\:\\ 0\\.04492451214565009\ \(0\)\
\-\ tuberculosis\\:\\ 0\\.04473171753410163\ \(0\)\
\-\ symmetric\\:\\ 0\\.04288861031022469\ \(0\)\
\-\ down\\:\\ 0\\.04030795546322028\ \(0\)\
\-\ progressive\\:\\ 0\\.03711471554992641\ \(0\)\
\-\ calcifications\\:\\ 0\\.034913887413546736\ \(0\)\
\-\ abnormalities\\:\\ 0\\.034491918919760625\ \(0\)\
\-\ calcification\\:\\ 0\\.03408555624678164\ \(0\)\
\-\ sclerosis\\:\\ 0\\.03372873882886094\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.03365874489165786\ \(0\)\
\-\ identified\\:\\ 0\\.03355458287017936\ \(0\)\
\-\ \\,\\:\\ 0\\.032723194732858917\ \(0\)\
\-\ benign\\:\\ 0\\.03240714689047474\ \(0\)\
\-\ radiation\\:\\ 0\\.030815947797388315\ \(0\)\
\-\ disease\\:\\ 0\\.030697528378367128\ \(0\)\
\-\ y\\.o\\:\\ 0\\.027103070687765938\ \(0\)\
\-\ syndrome\\:\\ 0\\.026856116227853204\ \(0\)\
\-\ therapy\\:\\ 0\\.025105942815830912\ \(0\)\
\-\ associated\\:\\ 0\\.02215892925173299\ \(0\)\
\-\ woman\\:\\ 0\\.021691241181196773\ \(0\)\
\-\ were\\:\\ 0\\.021321827875713423\ \(0\)\
\-\ treatment\\:\\ 0\\.019006779775833926\ \(0\)\
\-\ no\\:\\ 0\\.018910860455028617\ \(0\)\
\-\ there\\:\\ 0\\.013974896224889987\ \(0\)\
\-\ or\\:\\ 0\\.011005744494106677\ \(0\)\
\-\ for\\:\\ 0\\.008012177457612254\ \(0\)\
\-\ is\\:\\ 0\\.006179019542689293\ \(0\)\
\-\ with\\:\\ 0\\.0025715203536239503\ \(0\)\
\-\ and\\:\\ 0\\.001978120942112291\ \(0\)\
\-\ \\.\\:\\ 0\\.0019505239613926524\ \(0\)\
